As new therapies move through development and toward commercialization, manufacturing and fill-finish decisions become increasingly critical to program success. Challenges that appear manageable during early development can later emerge as formulation issues, technology transfer hurdles, capacity constraints, supply chain disruptions, and aseptic processing risks that impact timelines and product quality.
Successfully navigating these complexities requires a comprehensive understanding of process development, biologics manufacturing, sterile fill-finish operations, and CDMO partnership strategies. In this edition of the Outsourced Pharma Capabilities Update (OPCU), explore how leading CDMOs are helping sponsors streamline development, maintain product integrity, optimize technology transfer, and build scalable manufacturing strategies. Watch the presentations below to learn how different manufacturing and outsourcing approaches can support successful progression from clinical development through commercial launch.
Recent Sessions Available On-Demand
Cell Therapy & Cell Line Development – July 2026
ADCs And Microbial Development & Manufacturing – July 2026
Upcoming OPCU Topics & Times
CPHI Special Edition | 8/27/2026, AM Session
Fill/Finish | 9/1/2026, AM Session
ADCs | 9/11/2026, AM Session
AI Innovation in Drug Development & Manufacturing | 9/29/2026, AM Session
Viral Vectors | 9/29/2026, PM Session
mRNA | 9/30/2026, AM Session
Packaging, Labeling, & Logistics Services | 9/30/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
